In lung cancer treatment, Stereotactic Ablative Radiotherapy (SABR) is rapidly been used as an important radiation tool. SABR is being evaluated for treatment of medically inoperable lung cancer, operable lung cancers, metastases…
Tag: New Lung Cancer Treatment
Nanoparticle Vaccine Could Curb Lung Cancer Metastasis
The engineers at the University of California San Diego have come up with an experimental vaccine that could prevent the spread of metastatic cancers to the lung. The key ingredients of this…
J & J Lung Cancer Therapy Succeeds in Study with AstraZeneca’s Drug, Tagrisso
A head-to-head matchup between Johnson & Johnson combination and AstraZeneca’s drug, Tagrisso as a first-line treatment for non-small cell lung cancer has yielded J & J as the winner. In the MARIPOSA…
Tumor Treating Fields to Improve Survival Benefit in Lung Cancer
Tumor Treating Fields (TTFields) are electric fields that disrupt processes which are critical for the survival of cancer cells. This leads to immunogenic cell death and enhanced antitumor immune response. The use…
Quratusugene Ozeplasmid for Small Cell Lung Cancer Receives Orphan Drug Designation by FDA
Genprex, Inc. is a clinical-stage gene therapy company and has announced the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the drug, Reqorsa Immunogene Therapy (quratusugene…
Lung Cancer Drug, Osimertinib, Drastically Reduces Death Risk after Surgery
Lung cancer is among most common types of cancers in U.S. as well as around the world. According to the Centers for Disease Control and Prevention, it is responsible for nearly a…
Lung Cancer Outcomes May Be Improved By Chemo With TKI Drug
Gefitinib and chemotherapy may be considered a first-line treatment option for patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC) with brain metastases. Recent research has shown that patients with Epidermal Growth Factor…
FDA Approves Adjuvant Pembrolizumab for Non-Small Cell Lung Cancer Treatment
The US Food and Drug Administration has approved Pembrolizumab for adjuvant treatment following resection and platinum-based chemotherapy in patients with NSCLC (non-small cell lung cancer). This approval has been based on the…